WASHINGTON (Reuters) - AstraZeneca LP (L:AZN) has agreed to pay $46.5 million (£29.81 million) and Cephalon Inc [TEVAE.UL] $7.5 million to resolve allegations that the two drug companies underpaid rebates owed under the Medicaid program, the U.S. Justice Department said on Monday.